Buscar
Mostrando ítems 1-1 de 1
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the ...